Trial · NCT00843284
Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA
NCT00843284, Completed, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; results first posted 2009-04-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA. Trials, record NCT00843284. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00843284
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA
- NCT number
- NCT00843284
- Status
- Completed
- Enrollment
- 691 participants, actual
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Conditions
- Neuropathic Pain
- Interventions
- Pregabalin
- First posted
- 2009-02-13
- Last updated
- 2021-02-10
- Results first posted
- 2009-04-16
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Daily Average Pain Scores | Baseline, Final Visit (Week 8 or discontinuation) | Change is observed value at final visit (Week 8 or discontinuation) minus baseline value. Daily average pain score is measured using a 10-point Likert scale where 0 = no pain to 10 = pain as bad as you can imagine. |
| Primary | Pain Related Sleep Interference | Baseline, Final Visit (Week 8 or discontinuation) | Change is observed value at final visit (Week 8 or discontinuation) minus baseline value. Pain related sleep interference is measured by a 10-point Likert scale where 0 = does not interfere with sleep, and 10 = completely interferes with sleep |
| Secondary | Anxiety and Depression Symptoms | Baseline, Final Visit (Week 8 or discontinuation) | The presence of anxiety and depression symptoms were measured, based on how often the subject felt a certain emotion over the past week. Q1:Have you felt calm and relaxed? Q2: Have you felt full of energy? Q3: Have you felt discouraged and sad? Final Visit = Week 8 or time of discontinuation. |
| Secondary | Clinician Global Improvement of Change (CGIC) at Final Visit (Week 8 or Discontinuation) | Final Visit (Week 8 or discontinuation) | Clinician Global Improvement of Change (CGIC) indicates the change of the severity of the condition from baseline, graded from "very much improved" to "very much worse". |
| Secondary | Patient Global Improvement of Change (PGIC) at Final Visit (Week 8 or Discontinuation) | Final Visit (Week 8 or discontinuation) | Patient Global Improvement of Change (PGIC) indicates the change of severity of conditions from baseline, graded from "very much improved" to "very much worse". |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Anxiety and Depression Symptoms | Baseline, Final Visit (Week 8 or discontinuation) | Full analysis set (FAS). Full analysis set was derived from the set of all enrolled subjects who were administered the study medication and had post baseline documentation of efficacy. Last observation carried forward method (LOCF) was used. | participants | NUMBER |
| PRIMARY | Daily Average Pain Scores | Baseline, Final Visit (Week 8 or discontinuation) | Full analysis set (FAS). Full analysis set was derived from the set of all enrolled subjects who were administered the study medication and had post baseline documentation of efficacy. Last observation carried forward (LOCF) method was used. | scores on scale | MEAN |
| PRIMARY | Pain Related Sleep Interference | Baseline, Final Visit (Week 8 or discontinuation) | Full analysis set (FAS) was derived from the set of all enrolled subjects who were administered the study medication and had post baseline documentation of efficacy. Last observation carried forward (LOCF) method was used. | scores on a scale | MEAN |
| SECONDARY | Clinician Global Improvement of Change (CGIC) at Final Visit (Week 8 or Discontinuation) | Final Visit (Week 8 or discontinuation) | Full analysis set (FAS). Full analysis set was derived from the set of all enrolled subjects who were administered the study medication and had post baseline documentation of efficacy. Last observation carried forward (LOCF) method was used. Three subjects were not included in the analysis due to incomplete case report forms. | participants | NUMBER |
| SECONDARY | Patient Global Improvement of Change (PGIC) at Final Visit (Week 8 or Discontinuation) | Final Visit (Week 8 or discontinuation) | Full analysis set (FAS). Full analysis set was derived from the set of all enrolled subjects who were administered the study medication and had post baseline documentation of efficacy. Last observation carried forward (LOCF) method was used. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Always | 8 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Most of the time | 14 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Fairly often | 57 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Sometimes | 199 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Rarely | 186 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Never | 183 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Missing | 0 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at baseline: Not done | 21 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at final visit: Always | 27 | participants | |
| Anxiety and Depression Symptoms | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | Q1 at final visit: Most of the time | 152 | participants |
1 to 10 of 72Source ClinicalTrials.gov
See all 72 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 691 | |
| Overall Study | COMPLETED | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 619 | |
| Overall Study | NOT COMPLETED | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 72 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 133 | 691 | |
| other | Somnolence | Surgical and medical procedures | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 67 | 691 | |
| serious | Cardiopulmonary failure | Cardiac disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 | |
| serious | Abdominal pain | Gastrointestinal disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 | |
| serious | Nausea | Gastrointestinal disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 | |
| serious | Asthenia | General disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 | |
| serious | Death | General disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 3 | 691 | |
| serious | Fatigue | General disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 | |
| serious | Tremor | Nervous system disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 | |
| serious | Dysphoria | Psychiatric disorders | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 1 | 691 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | ||
| Total, other adverse events | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 151 | |
| Total, serious adverse events | Pregabalin (150 mg to 600 mg Per Day in 2 to 3 Divided Doses) | 7 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00843284
GET https://conductscience.org/api/trials/v1/NCT00843284/results?page=2